{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-010964","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.509105+00:00","generated_at":"2026-06-29T18:08:48.185377+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros Q2 OMIDRIA rev $28.8M (+37% QoQ); narsoplimab PDUFA Oct 17","bullets":["OMIDRIA revenue $28.8M in Q2 2021, up 37% from Q1 $21.1M; net loss narrowed to $28.6M ($0.46/sh) from $35.1M.","Narsoplimab BLA for HSCT-TMA under FDA priority review with PDUFA action date Oct 17, 2021.","Preliminary Phase 1 data for OMS906 (MASP-3 inhibitor) show well tolerated, PK/PD consistent with monthly SC dosing.","CMS proposed rule reaffirms separate payment for OMIDRIA in ASCs for 2022.","Cash & investments $73.7M; $150M ATM program available; $50M line of credit."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-010964","json":"https://secwatch.observer/filing/0001558370-21-010964.json","markdown":"https://secwatch.observer/filing/0001558370-21-010964.md","text":"https://secwatch.observer/filing/0001558370-21-010964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/0001558370-21-010964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837021010964/omer-20210809x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T18:08:48.185377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}